CD5 Antibody (SPM546), Novus Biologicals™

CD5

Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 0.5-1ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1.0ug/ml, Immunohistochemistry-Frozen 0.5-1.0ug/ml

Monoclonal

Purified

RUO

Human

P06127

921

Human CD5 recombinant protein

Primary

Store at 4C.

67 kDa

SPM546

Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin)

Unconjugated

Mouse

Adaptive Immunity, Cell Biology, Cytokine Research, Immunology, Phospho Specific

PBS with 0.05% BSA. with 0.05% Sodium Azide

CD5 antigen, CD5 antigen (p56-62), CD5 molecule, LEU1T-cell surface glycoprotein CD5, Lymphocyte antigen T1/Leu-1, T1

CD5

IgG1 κ

Protein A purified

Recognizes a 67kDa transmembrane protein, which is identified as CD5. The CD5 antigen is found on 95% of thymocytes and 72% of peripheral blood lymphocytes. In lymph nodes, the main reactivity is observed in T cell areas. Anti-CD5 is a pan T-cell marker that also reacts with a range of neoplastic B-cells, e.g. chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma, and a subset (∼10%) of diffuse large B-cell lymphoma. CD5 aberrant expression is useful in making a diagnosis of mature T-cell neoplasms. Anti-CD5 detection is diagnostic in CLL/SLL within a panel of other B-cell markers, especially one that includes anti-CD23. Anti-CD5 is also very useful in differentiating among mature small lymphoid cell malignancies. In addition, anti-CD5 can be used in distinguishing thymic carcinoma (+) from thymoma (-). Anti-CD5 does not react with granulocytes or monocytes.